EUDA Health Holdings Limited announced on August 28, 2025, that it has signed a Letter of Intent (LOI) to potentially acquire Chemokine Pte Ltd. Chemokine is a Singapore-based biotech company focused on immune health, from which EUDA recently secured distribution rights for a next-generation immune health supplement.
Under the terms of the LOI, EUDA will conduct due diligence on Chemokine, subject to confidentiality obligations. Chemokine has agreed to an exclusivity period of at least one month to facilitate this process.
This potential acquisition signifies EUDA's ongoing strategy to expand its advanced biotechnology and wellness product portfolio. A successful acquisition would further integrate Chemokine's expertise and products into EUDA's growing ecosystem, strengthening its position in the longevity sector.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.